CN111514179A - Application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process - Google Patents
Application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process Download PDFInfo
- Publication number
- CN111514179A CN111514179A CN202010486967.0A CN202010486967A CN111514179A CN 111514179 A CN111514179 A CN 111514179A CN 202010486967 A CN202010486967 A CN 202010486967A CN 111514179 A CN111514179 A CN 111514179A
- Authority
- CN
- China
- Prior art keywords
- tripterygium glycosides
- phellinus igniarius
- application
- phellinus
- tripterygium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000545405 Tripterygium Species 0.000 title claims abstract description 39
- 229930182470 glycoside Natural products 0.000 title claims abstract description 37
- 150000002338 glycosides Chemical class 0.000 title claims abstract description 37
- 241000123113 Phellinus igniarius Species 0.000 title claims abstract description 34
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 title claims abstract description 28
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title description 9
- 230000008569 process Effects 0.000 title description 7
- 241000001727 Tropicoporus linteus Species 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000830536 Tripterygium wilfordii Species 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 235000015398 thunder god vine Nutrition 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 15
- 241000700159 Rattus Species 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 210000002700 urine Anatomy 0.000 abstract description 10
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 6
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 6
- 102000004420 Creatine Kinase Human genes 0.000 abstract description 6
- 108010042126 Creatine kinase Proteins 0.000 abstract description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 3
- 208000013875 Heart injury Diseases 0.000 abstract description 2
- 108010044467 Isoenzymes Proteins 0.000 abstract description 2
- 206010061481 Renal injury Diseases 0.000 abstract description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 abstract description 2
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 229960003624 creatine Drugs 0.000 abstract description 2
- 239000006046 creatine Substances 0.000 abstract description 2
- 229940109239 creatinine Drugs 0.000 abstract description 2
- 208000037806 kidney injury Diseases 0.000 abstract description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 2
- 108010077078 Creatinase Proteins 0.000 abstract 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 9
- 238000011160 research Methods 0.000 description 6
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000007721 medicinal effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000003563 glycoside group Chemical group 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000123107 Phellinus Species 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010061989 glomerulosclerosis Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000013059 nephrectomy Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241001556385 Sanghuangporus baumii Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 102000045921 human GAA Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940103023 myozyme Drugs 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000022204 primary glomerular disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis. The phellinus igniarius combined with tripterygium glycosides can obviously reduce urine protein, reduce blood creatinine and urea nitrogen of rats, reduce serum triglyceride, cholesterol and low-density lipoprotein, and reduce the amount of creatine kinase, creatine creatinase isoenzyme and glutamic-pyruvic transaminase. The phellinus igniarius decoction is used in combination with the tripterygium glycosides, so that the toxicity of the tripterygium glycosides can be reduced, the heart injury can be improved on the basis of ensuring the effects of relieving the kidney injury, reducing the blood fat and the like of FSGS rats, and the application prospect is wide.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and in particular relates to an application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis.
Background
Chronic Kidney Disease (CKD) has become a serious disease that seriously threatens human health. Recent epidemiological survey results show that the prevalence of CKD in our country is 10.8% (about 1.2 hundred million). Focal Segmental Glomerulosclerosis (FSGS) particularly refers to a common primary glomerular disease, which is characterized by Focal and segmental sclerosis as main pathological features, clinically manifested as proteinuria, with a tendency of increasing incidence year by year, and is very easy to progress into end-stage renal disease (ESRD). Therefore, there is a need to find a safe and effective way to slow the progress of FSGS.
Currently, the treatment of FSGS mainly comprises glucocorticoid, immunosuppressant and cytotoxic drugs, but the reactions are poor, the occurrence and the progress of FSGS cannot be controlled ideally, and side effects are difficult to avoid in the using process. The traditional Chinese medicine has the advantages of multiple links and multiple targets for treating diseases, and has better clinical curative effect on preventing and treating the kidney diseases. The tripterygium wilfordii and the active ingredients thereof which are widely applied clinically have unique advantages in the field of treating the intractable nephrotic syndrome, and the defect of beauty is that the tripterygium wilfordii has large toxic and side effects and can cause liver and kidney injury to a certain extent. Therefore, there is an urgent need to find a new safe and effective drug that can delay the FSGS process.
Phellinus igniarius (Phellinus igniarius)Phellinus baumii) It is also called as sang chen and sang Er, and is a precious medical fungus parasitic on broad-leaved trees such as mulberry, and is known as forest gold. The medicinal effect is recorded in the compendium of materia medica for the earliest time, the medicinal effect is slightly bitter, the medicinal effect can benefit five internal organs, soften hard masses, expel toxin, stop bleeding, activate blood and the like, and the medicinal effect is matched with the Chinese medicine pathogenesis category 'stasis' and 'toxicity' of the Chinese medical scholars understanding glomerulosclerosis at home. Modern pharmacological research proves that phellinus igniarius contains various components such as polysaccharide, flavone, terpenes, pyrones and the like, and has pharmacological effects of resisting tumors, reducing blood sugar, protecting liver, resisting inflammation, regulating immunity, resisting oxidation and the like. At present, phellinus igniarius is internationally recognized as the most effective anticancer agentOne of the good large medicinal fungi. In addition, recent studies have revealed that phellinus linteus also has a certain anti-hepatic fibrosis effect. In view of its wide biological action, Phellinus igniarius has become a hot point for research in the medical and health product industries at home and abroad, and is concerned by scholars at home and abroad. Although the research on Phellinus linteus covers many of the above-mentioned fields and new research is emerging, research and application of Phellinus linteus in the protection of chronic kidney disease and the like have been recently reported at home and abroad, and no relevant description has been found in ancient books.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide the application of the combination of phellinus igniarius and tripterygium glycosides in delaying the focal segmental glomerulosclerosis process.
The technical purpose of the invention is realized by the following technical scheme:
an application of Phellinus Linteus and Tripterygium Wilfordii polyglycoside in delaying focal segmental glomerulosclerosis is provided.
Further, the phellinus igniarius is a phellinus igniarius decoction.
Further, the preparation method of the phellinus igniarius decoction comprises the following steps:
a. accurately weighing Phellinus Linteus powder, adding distilled water, soaking for 30 min, and decocting for 30 min;
b. filtering with double-layer gauze, and collecting filtrate;
c. adding distilled water into the residue, and decocting for 7 hr;
d. filtering with double-layer gauze, mixing filtrates, decocting, and concentrating to desired concentration.
Further, the amount of Phellinus linteus is 8 g.d-1。
Further, the use amount of the tripterygium glycosides is 60 mg/d.
The invention has the following beneficial effects:
the phellinus igniarius decoction is used in combination with the tripterygium glycosides, so that the toxicity of the tripterygium glycosides can be reduced, the heart injury can be improved and the like on the basis of ensuring the original effects of relieving the renal function injury, reducing blood fat and the like of FSGS rats. In conclusion, the sequential combined treatment of the phellinus igniarius decoction and the tripterygium glycosides can play a role in synergism and attenuation on the tripterygium glycosides, fully meets clinical requirements, and has practicability.
Drawings
FIG. 1 is a graph showing the effect of combined SANGHUANGHETRIPTIDE of the present invention on FSGS rat urinary protein;
FIG. 2 is a graph showing the effect of Phellinus linteus and Tripterygium wilfordii glycosides of the present invention on kidney function of FSGS rats.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings.
The medicaments for delaying the FSGS process mainly comprise the following components: the Phellinus igniarius decoction is combined with Tripterygium glycosides, and the dosage of Phellinus igniarius is 8 g.d reference adult dosage-1The dose of tripterygium glycosides is 60mg/d for adults (50 kg), and then the SD rat intervention dose is calculated according to the unit body surface area crude drug quantity.
The preparation method of the phellinus igniarius decoction comprises the following steps: accurately weighing Phellinus Linteus powder by conventional traditional Chinese medicine decocting method, adding distilled water, soaking for 30 min, decocting for 30 min, filtering with double-layer gauze, and collecting filtrate; adding distilled water into the residue, decocting for 7 hr, filtering with double-layer gauze, mixing filtrates, decocting, and concentrating to desired concentration. The usage and dosage are as follows: the stomach was gavaged 2mL once a day until the end of the experiment.
According to the quality of the tripterygium glycosides tablet, the dosage of each time is calculated, then the tripterygium glycosides tablet is fully ground into powder and directly dissolved in prepared phellinus igniarius decoction, and the compatibility of phellinus igniarius and tripterygium glycosides is realized.
The experimental process comprises the following steps: the FSGS rat Model is constructed by combining unilateral nephrectomy with adriamycin injection, and experiments are set as a Control group (Control), a Model group (Model) and a phellinus igniarius group (Phellinus baumiiPLB), Phellinus Linteus in combination with Tripterygium Wilfordii polyglycoside group (A)Phellinus baumiiand tripterygium Glycosides, PLB + TG), Tripterygium Glycosides (TG). Performing phellinus igniarius decoction intervention treatment the next day after operation, performing intragastric administration of 2mL once a day, and performing intragastric administration of the control group and the model group by using the same amount of water. Tripterygium glycosides intervention five weeks from surgery (protein)After urine appears) to begin intragastric administration. The combination group adopts sequential combination therapy, namely, the lavage of the phellinus igniarius decoction is started the next day of unilateral nephrectomy, and the lavage treatment of the tripterygium glycosides combined with the phellinus igniarius decoction is carried out from the fifth week.
The syndrome differentiation mechanism of traditional Chinese medicine is as follows: tripterygium glycosides are the extract of radix Tripterygii Wilfordii without peel, contain effective components such as diterpene, alkaloid and triterpene, and have good effects in treating primary glomerulonephritis, minimal change and albuminuria. However, researches show that tripterygium glycosides still have certain toxic and side effects, can damage the liver and the heart, and have certain renal toxicity. Clinically, patients in the later stage of chronic nephropathy need to take the medicine without toxicity, which limits the use of tripterygium glycosides. The traditional Chinese medicine is characterized in that the principle of 'monarch, minister, assistant and guide' is studied, and the effects of the phellinus igniarius in benefiting the five internal organs, expelling toxin, stopping bleeding, invigorating blood circulation and the like are considered, so that the phellinus igniarius is matched with the 'stasis' and 'toxicity' in the traditional Chinese medicine pathogenesis category of understanding of glomerulosclerosis by Chinese medical scholars in China.
Measurement method
Collecting 24 h urine of each group of rats by using a metabolism cage method in the fourth week and the tenth week of the experiment respectively, centrifuging at 3000 rpm/min for 10min, removing sediments, collecting supernatant, and measuring the total amount of 24 h urine protein on a full-automatic biochemical analyzer (HITACHI 7180).
At the end of the experiment, the abdominal aorta was bled, centrifuged at 3000 rpm/min for 10min in a 37 ℃ water bath for 1 h, the supernatant was aspirated, and the measurement of Scr, BUN, TG, TC, LDL, CK-MB and ALT was performed on a fully automatic biochemical analyzer.
Example 1 Effect of Phellinus linteus and Tripterygium glycosides on FSGS rat urine protein
The experimental result is shown in fig. 1, the 24 h total urine protein (24 h urine protein, 24 h Pro) of the model group is significantly higher than that of the control group, the 24 h urine protein of the phellinus igniarius group and each intervention group is lower than that of the model group, the phellinus igniarius combined with the tripterygium glycosides group in the tenth week significantly reduces the urine protein compared with the model group, and the phellinus igniarius or the tripterygium glycosides can also significantly reduce the urine protein by single intervention, but has no statistical significance compared with the model group.
Example 2 Effect of Phellinus linteus and Tripterygium glycosides on FSGS rat Kidney function
The experimental results are shown in fig. 2, the Serum creatinine (Scr) and urea nitrogen (BUN) of rats in the model group are significantly increased compared with those in the control group, the Scr value of each intervention group is significantly lower than that of the model group, the BUN of the phellinus igniarius combined tripterygium glycosides group is significantly lower than that of the model group, and is significantly lower than that of the phellinus igniarius or the tripterygium glycosides independent intervention group, and the BUN level of the single administration group has no statistical significance with the difference between the model groups.
Example 3 Effect of Phellinus linteus and Tripterygium glycosides on FSGS rat blood lipid
The experimental results are shown in table 1, serum Triglyceride (TG), Cholesterol (TC) and Low Density Lipoprotein (LDL) in the FSGS kidney rat model group are all significantly increased compared with the control group, TG and TC in each dry pretreatment group are significantly lower than those in the model group, LDL level in the multi-glycoside group of the common threewingnut root combined with phellinus linteus is significantly lower than that in the model group, TG and LDL level are significantly lower than those in the single dry pretreatment group of phellinus linteus or common threewingnut root without statistical significance.
TABLE 1
Note: in comparison with the normal group, a pless than 0.05; in comparison with the set of models, b p＜0.05。
example 4 Effect of Phellinus linteus and Tripterygium glycosides on FSGS rat creatine kinase, creatine myozyme and glutamic-pyruvic transaminase
The experimental results are shown in table 2, the Creatine Kinase (CK) and creatine kinase isoenzyme (CK-MB) and Alanine transaminase (ALT) of the model group are obviously higher than those of the control group, the CK and CK-MB of each intervention group are obviously reduced compared with the model group, but the difference between the tripterygium glycosides group with phellinus linteus and the model group has statistical significance; there was no statistical difference between ALT levels in each stem group and model groups.
TABLE 2
Note: in comparison with the normal group, a pless than 0.05; in comparison with the set of models, b p＜0.05。
the embodiments of the present invention are preferred embodiments of the present invention, and the scope of the present invention is not limited by these embodiments, so: all equivalent changes made according to the structure, shape and principle of the invention are covered by the protection scope of the invention.
Claims (5)
1. An application of Phellinus Linteus and Tripterygium Wilfordii polyglycoside in delaying focal segmental glomerulosclerosis is provided.
2. The use of phellinus linteus and tripterygium glycosides in combination according to claim 1 for delaying the progression of focal segmental glomerulosclerosis, wherein: the Phellinus linteus is a Phellinus linteus decoction.
3. The use of phellinus linteus and tripterygium glycosides in combination according to claim 2 for delaying the progression of focal segmental glomerulosclerosis, wherein: the preparation method of the phellinus igniarius decoction comprises the following steps:
a. accurately weighing Phellinus Linteus powder, adding distilled water, soaking for 30 min, and decocting for 30 min;
b. filtering with double-layer gauze, and collecting filtrate;
c. adding distilled water into the residue, and decocting for 7 hr;
d. filtering with double-layer gauze, mixing filtrates, decocting, and concentrating to desired concentration.
4. The use of phellinus linteus and tripterygium glycosides in combination according to claim 1 for delaying the progression of focal segmental glomerulosclerosis, wherein: the usage amount of Phellinus Linteus is 8 g.d-1。
5. The use of phellinus linteus and tripterygium glycosides in combination according to claim 1 for delaying the progression of focal segmental glomerulosclerosis, wherein: the application amount of the tripterygium glycosides is 60 mg/d.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010486967.0A CN111514179B (en) | 2020-06-02 | 2020-06-02 | Application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010486967.0A CN111514179B (en) | 2020-06-02 | 2020-06-02 | Application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111514179A true CN111514179A (en) | 2020-08-11 |
| CN111514179B CN111514179B (en) | 2021-07-23 |
Family
ID=71907854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010486967.0A Active CN111514179B (en) | 2020-06-02 | 2020-06-02 | Application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111514179B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350476B1 (en) * | 2000-05-22 | 2002-02-26 | Shanxi Zhengzhon Pharmaceutical Co., Ltd. | Herbal chinese joint complex |
-
2020
- 2020-06-02 CN CN202010486967.0A patent/CN111514179B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350476B1 (en) * | 2000-05-22 | 2002-02-26 | Shanxi Zhengzhon Pharmaceutical Co., Ltd. | Herbal chinese joint complex |
Non-Patent Citations (2)
| Title |
|---|
| 邹佳涵等: "雷公藤多苷片治疗慢性肾小球肾炎的系统综述及GＲADE证据级别评价", 《时珍国医国药》 * |
| 黄倩: "桑黄多糖通过P311 /TGF － β1 /Snail1 通路抗糖尿病小鼠肾间质纤维化的研究", 《中药药理与临床》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111514179B (en) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8883228B2 (en) | Composition for heart disease, its active ingredients, method to prepare same and uses thereof | |
| JP5232152B2 (en) | Drug composition having therapeutic action for type 2 diabetes and chronic complications of type 2 diabetes | |
| JP4657714B2 (en) | Compositions for heart disease, methods for preparing the compositions, and uses thereof. | |
| CN1742763A (en) | Use of Wucenglong extract in preparing health-care product and medicines | |
| CN102228517B (en) | Plantain seed extract and application thereof | |
| Chang et al. | A triterpenoid-enriched extract of bitter melon leaves alleviates hepatic fibrosis by inhibiting inflammatory responses in carbon tetrachloride-treated mice | |
| CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
| WO2003086425A1 (en) | An anti-rheumatism medicament and method to prepare thereof | |
| CN107137450B (en) | Pharmaceutical composition and application thereof | |
| CN109078134A (en) | It is a kind of that not only there is Chinese medicine composition and preparation method thereof that is anti-oxidant but also can reduce gout patients serum Uric Acid Concentration | |
| CN111514179B (en) | Application of combined application of phellinus igniarius and tripterygium glycosides in delaying focal segmental glomerulosclerosis process | |
| KR20110078525A (en) | Composition for improving hepatic function containing ginseng berry extracts | |
| CN115444893B (en) | Uric acid reducing active substance composition and application thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| US20120071431A1 (en) | Platycodin Radix Extracts, and Their Use in Treating Disease Conditions Associated with Angiogenesis | |
| YOKOZAWA et al. | Inhibitory effects of ginseng on proliferation of cultured mouse mesangial cells | |
| CN105982887A (en) | Application of arctigenin in preparing medicine for treating blood hyperviscosity | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN102631502B (en) | Medicament for preventing and treating atherosclerosis and preparation method of granular formulation | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN105943583B (en) | Sweet wormwood herb and red yeast rice composition and application thereof | |
| CN108420842A (en) | A kind of sowthistle-leaf ixeris seedling preparation of antigout effect | |
| CN114886964B (en) | Traditional Chinese medicine composition for treating drug-induced liver injury and preparation method thereof | |
| CN100336526C (en) | Medicine composition for treating diabetes and preparing method | |
| CN101108220A (en) | Medicine for treating hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |